课题基金 / 基金详情

SAFETY, TOLERANCE & PK STUDY OF RISING DOSE MSI 1256F (SQUALAMINE LACTATE)

SAFETY, TOLERANCE & PK STUDY OF RISING DOSE MSI 1256F (SQUALAMINE LACTATE)
安全、宽容
批准号：
6450060
负责人：
S. Gail Eckhardt
金额：
$23.48万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2000
资助国家：
美国
项目状态：
已结题
起止时间：
2000-12-01 至 2001-11-30
来源：
https://reporter.nih.gov/project-details/6450060
关键词：
antineoplastics cholestane compound clinical research clinical trial phase I dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation neoplasm /cancer chemotherapy neoplastic process pharmacokinetics

项目摘要

项目成果

S. Gail Eckhardt的其他基金

相关文献

中文摘要
翻译
研究药物乳酸角鲨胺通过抑制肿瘤的血液供应而抑制实体肿瘤的生长，而不会对肿瘤细胞产生直接的细胞毒性。它之前还没有在人体上进行过测试。本研究的目的是确定该药的最大耐受量，确定其定性和定量毒性特征，确定连续5天给药的推荐剂量，并对该药的药代动力学和药效学特性进行表征。
英文摘要
The study drug, squalamine lactate, inhibits growth of solid tumors by inhibiting the development of a blood supply to the tumor without direct cytotoxicity to tumor cells. It has not been previously tested in human subjects. The purposes of this study are to determine the maximum tolerated dosage, determine the qualitative and quantitative toxicity charcteristics, determine the recommended dose as a continuous five day infusion, and characterize the pharmacokinetic and pharmacodynamic charcteristcs of the drug.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium